ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM

Their core work

Amsterdam UMC (AMC) is one of the Netherlands' leading academic medical centers, combining clinical care with biomedical research across cardiovascular disease, immunology, infectious diseases, and cancer biology. Their H2020 portfolio shows deep strength in training the next generation of biomedical researchers through Marie Skłodowska-Curie networks, alongside running large-scale clinical and translational research programs. They are particularly strong in epigenetics of immune regulation, cardiac arrhythmia research, and in silico clinical trial modeling. Their work bridges fundamental molecular biology with direct clinical applications, making them a natural partner for both basic science consortia and industry-driven medical device or pharma collaborations.

What they specialise in

How they've shifted over time

In the early H2020 period (2014-2018), AMC focused heavily on metabolic and chronic disease research — diabetes prevention in South Asian populations, glucose homeostasis across the lifecourse, obesity, inflammatory bowel disease, and urinary incontinence eHealth solutions. Their later projects (2018-2022) shifted toward more mechanistic and computational approaches: in silico stroke trials with virtual patient populations, systems medicine, host-pathogen genomics, germinal centre B-cell biology, and cardiac arrhythmia mechanisms. This evolution shows a move from population-level epidemiology and clinical management toward molecular-level understanding and digital modeling of disease.

AMC is moving toward in silico clinical trials and systems biology approaches, positioning itself at the intersection of computational modeling and translational medicine — a strong fit for digital health and medtech consortia.

How they like to work

AMC operates as both a consortium leader and a strong contributing partner, with a near-even split of 23 coordinated vs 25 participant roles — unusual balance that shows they can drive projects or integrate into others' visions equally well. With 302 unique consortium partners across 34 countries, they function as a major European hub rather than relying on a small circle of repeat collaborators. Their large MSCA training network involvement (14 projects) means they are experienced at managing multi-site doctoral programs and early-career researcher exchanges, which requires strong administrative coordination capacity.

AMC has built an extensive network of 302 unique partners across 34 countries, making them one of the most broadly connected medical research institutions in H2020. Their reach spans most EU member states plus associated countries, with particularly strong ties in Western European clinical research networks.

What sets them apart

AMC stands out among European academic medical centers for its exceptional breadth — spanning immunology, cardiology, oncology, infectious disease, and computational medicine within a single institution, all with strong H2020 track records. Their willingness to coordinate large projects (23 as lead, including EUR 2.6M ESCAPE-NET) while simultaneously running numerous MSCA training networks makes them a rare dual-capability partner: they can both lead ambitious research agendas and train the workforce to deliver them. For industry partners, their INSIST project demonstrates concrete experience bridging academic research with medical device and pharma industry needs through in silico trial design.

Highlights from their portfolio

• ESCAPE-NET
  Largest AMC-coordinated project (EUR 2.6M) building a European sudden cardiac arrest database for prevention, treatment, and genetic epidemiology — a flagship clinical network.
• INSIST
  Pioneered in silico clinical trials for stroke treatment using virtual patient populations, directly relevant to medical device and pharmaceutical industry regulatory needs.
• REPROGRAM
  Coordinated a project linking epigenetic reprogramming of innate immunity to atherosclerosis and chronic inflammatory diseases — a translational bridge between basic immunology and cardiovascular medicine.